Catherine Richon

Catherine Richon

UNVERIFIED PROFILE

Are you Catherine Richon?   Register this Author

Register author
Catherine Richon

Catherine Richon

Publications by authors named "Catherine Richon"

Are you Catherine Richon?   Register this Author

22Publications

740Reads

6Profile Views

Correction of the FSHD myoblast differentiation defect by fusion with healthy myoblasts.

J Cell Physiol 2016 Jan;231(1):62-71

UMR 8126, University of Paris-Sud, CNRS, Institut de Cancérologie Gustave-Roussy, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.25110DOI Listing
January 2016

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

Neuro Oncol 2015 Jul 21;17(7):953-64. Epub 2014 Dec 21.

CNRS UMR 8203 Vectorology and Anticancer Therapeutics, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (N.T., C.P., F.A., L.G.-R., G.C., L.L.-D., B.G., G.V., J.G.); Functional Genomics Unit, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (C.R.); Translational Research Laboratory and Biobank, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (L.L.); Inserm U981, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (L.L.); Department of Medical Biology and Pathology, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (L.L.); Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Institute, Paris XI University, Villejuif, France (B.G., J.G.); Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden (J.P., A.Ö.); Department of Neurosurgery, Necker-Sick Children Hospital, Paris Descartes University, Paris, France (S.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654348PMC
July 2015

hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

J Mol Med (Berl) 2011 Apr 8;89(4):411-21. Epub 2011 Feb 8.

Institut National de la Santé et de la Recherche Médicale U753; Laboratoire d'immunologie des tumeurs humaines: interaction effecteurs cytotoxiques-système tumoral, Institut Gustave Roussy PR1 and IFR 54, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-010-0708-0DOI Listing
April 2011

Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.

Int Immunol 2008 Jul 25;20(7):801-10. Epub 2008 Apr 25.

Institut National de Santé et de Recherche Médicale U753, Laboratoire Immunologie des Tumeurs humaines: Interaction Effecteurs Cytotoxiques-Système Tumoral, Institut Fédératif de Recherche-54, Institut Gustave Roussy, 94805 Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxn038DOI Listing
July 2008

Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells.

J Biol Chem 2007 Nov 13;282(45):32991-9. Epub 2007 Sep 13.

INSERM U753, Laboratoire d'Immunologie des Tumeurs Humaines, Interaction Effecteurs Cytotoxiques-Système Tumoral, Institut Gustave Roussy PR1, IFR 54,Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M705290200
Publisher Site
http://dx.doi.org/10.1074/jbc.M705290200DOI Listing
November 2007

Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death.

J Immunol 2007 Jun;178(11):6821-7

Laboratoire "Immunologie des tumeurs humaines: Interaction effecteurs cytotoxiques-système tumoral," Institut National de la Santé et de la Recherche Médicale Unité 753, Institut Fédératif de Recherche 54, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.178.11.6821DOI Listing
June 2007

p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways.

J Immunol 2005 Jan;174(2):871-8

Laboratoire Cytokines et Immunologie des Tumeurs Humaines, Unité 487 Institut National de la Santé et de la Recherche Médicale, Institut Fédératif de Recherche 54, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.174.2.871DOI Listing
January 2005

[Tumor/cytotoxic effector cross-talk in the control of tumor susceptibility to lysis].

Bull Cancer 2003 Aug-Sep;90(8-9):686-94

Inserm U487, IFR 54, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
December 2003

Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function.

J Immunol 2003 Jun;170(12):5919-26

Laboratoire Cytokines et Immunologie des Tumeurs Humaines, Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Fédératif de Recherche 54 Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.170.12.5919DOI Listing
June 2003